Resistencia antimicrobiana en aislados clínicos de Pseudomonas aeruginosa

Casal, María del Mar; Causse, Manuel; Rodríguez-López, Fernando; Casal, Manuel.
Rev. esp. quimioter ; 25(1): 37-41, mar. 2012. tab
Artículo en Español | IBECS (España) | ID: ibc-99751

Documentos relacionados

  1. Antimicrobial resistance, virulence factors, and genotypes of Pseudomonas aeruginosa clinical isolates from Gorgan, northern Iran.
  2. [Pseudomonas aeruginosa bacteremia: associations with a source of infection and antibiotic resistance].
  3. Incidence of ESBLs and carbapenemases among Enterobacterales and carbapenemases in Pseudomonas aeruginosa isolates collected globally: results from ATLAS 2017-2019.
  4. A simulation study on model-informed precision dosing of amikacin for achieving target area under the concentration-time curve.
  5. Amikacin Pharmacokinetic-Pharmacodynamic Analysis in Pediatric Cancer Patients.
  6. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa.
  7. Pharmacodynamics of Aerosolized Fosfomycin and Amikacin against Resistant Clinical Isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a Hollow-Fiber Infection Model: Experimental Basis for Combination Therapy.
  8. Activity of Cefiderocol and Comparators against Isolates from Cancer Patients.
  9. Ceftazidime/avibactam versus standard-of-care agents against carbapenem-resistant Enterobacteriaceae harbouring blaKPC in a one-compartment pharmacokinetic/pharmacodynamic model.
  10. In vitro activity of ceftazidime-avibactam against Gram-negative strains in Chile 2015-2021.